Abstract
Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). In clinical trials, subcutaneous (SC) golimumab injected every 4 weeks significantly improved clinically relevant end points in all 3 disease states. In patients with RA, golimumab is approved for use in combination with methotrexate (MTX); in patients with PsA or AS, golimumab may be used with or without MTX. Golimumab may increase the risk for upper respiratory tract infection, lymphoma, and injection-site reaction, but the incidence of these adverse events was low in clinical trials. (Formulary . 2009;44:264–272.)